CLINICAL TRIALS PROFILE FOR COLESTIPOL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for colestipol hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000512 ↗ | Familial Atherosclerosis Treatment Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00000512 ↗ | Familial Atherosclerosis Treatment Study | Completed | University of Washington | Phase 3 | 1984-01-01 | To compare the effects of two intensive lipid-lowering regimens with conventional therapy on coronary atherosclerosis as assessed by arteriography. |
| NCT00000599 ↗ | Cholesterol-Lowering Atherosclerosis Study (CLAS) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1980-06-01 | To determine whether combined therapy with the lipid lowering agents colestipol hydrochloride plus niacin would produce significant change in coronary, carotid, and femoral artery atherosclerosis and coronary bypass graft lesions as determined by angiography. Also, to determine possible correlations between lesion changes and plasma lipid and lipoprotein cholesterol levels and to explore interrelationships of atherosclerosis change in femoral, coronary, and carotid arteries. |
| NCT00116870 ↗ | MARS - Monitored Atherosclerosis Regression Study | Completed | Merck Sharp & Dohme Corp. | Phase 2/Phase 3 | 1985-06-01 | The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression. |
| NCT00203476 ↗ | A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction | Completed | American Society of Health-System Pharmacists Research and Education Foundation | Phase 4 | 2005-05-01 | To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. The patient's cardiovascular risks are assessed to determine if National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) guidelines for low density lipoprotein (LDL) reduction were achieved between the three groups. Secondary measures examine the safety issues with liver function test (LFT) monitoring and rhabdomyolysis. High-density lipoproteins (HDL) elevations are monitored between the three groups to determine efficacy as a secondary outcome. |
| NCT00203476 ↗ | A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction | Completed | Tuscaloosa Research & Education Advancement Corporation | Phase 4 | 2005-05-01 | To compare LDL reduction compared to baseline in patients using maximum tolerated HMG CoA Reductase inhibitor (statin) therapy with adjunctive therapy with ezetimibe, colestipol, or niacin. The patient's cardiovascular risks are assessed to determine if National Cholesterol Education Program's Adult Treatment Panel III (NCEP ATP III) guidelines for low density lipoprotein (LDL) reduction were achieved between the three groups. Secondary measures examine the safety issues with liver function test (LFT) monitoring and rhabdomyolysis. High-density lipoproteins (HDL) elevations are monitored between the three groups to determine efficacy as a secondary outcome. |
| NCT00307307 ↗ | Carotid Atherosclerosis Regression at Magnetic Resonance Assessment. | Completed | Kos Pharmaceuticals | Phase 4 | 2000-01-01 | The primary objective of this randomized, double blind, placebo controlled pilot study is to determine if therapies aimed at lowering LDL cholesterol (HMGCoA reductase inhibitor - simvastatin) or increasing HDL cholesterol (Niaspan) will induce regression of carotid atherosclerotic plaque in vivo using MRI imaging techniques. MR plaque morphology at baseline will be compared to that after 6 and 12 months of therapy and changes in MR characteristics will be compared to changes in lipoprotein parameters and urinary isoprostanes. The effect of moderate LDL reduction, aggressive LDL reduction and the combination of aggressive LDL reduction and HDL elevation on MRI plaque characteristics will be compared by randomly assigning subjects (n=69) with carotid disease (>30% stenosis by ultrasound criteria) to one of three treatment arms; 1. Simvastatin 20 mg daily and placebo Niaspan (n=23) 2. Simvastatin 80 mg daily and placebo Niaspan (n=23) 3. Simvastatin 20 mg daily and active Niaspan (n=23) Treatment group 2 and 3 will have roughly equivalent LDL lowering because of the synergistic LDL lowering effect of the combination of simvastatin and Niaspan. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for colestipol hydrochloride
Condition Name
Clinical Trial Locations for colestipol hydrochloride
Trials by Country
Clinical Trial Progress for colestipol hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for colestipol hydrochloride
Sponsor Name
